Parkinsons Flashcards

(55 cards)

1
Q

What are the core similarities between Alzheimer’s disease and Parkinson’s disease?

A

Both are neurodegenerative diseases.

Misfolding and aggregation of physiological proteins into pathological forms.

Accumulation of aggregated proteins in affected neurons causes dysfunction.

Both can lead to dementia in some patients.

Both are age-related conditions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the main differences between Alzheimer’s and Parkinson’s disease in terms of pathology and affected brain areas?

A

Alzheimer’s spreads from one brain region to others; Parkinson’s is classically localized.

Parkinson’s affects regions involved in movement (e.g., substantia nigra).

Alzheimer’s affects regions involved in short-term memory (e.g., hippocampus).

Pathological proteins differ:

Alzheimer’s: tau tangles and amyloid-β plaques

Parkinson’s: alpha-synuclein forms Lewy bodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the primary clinical symptoms of Parkinson’s disease?

A

Movement disorder: tremor, rigidity, and shuffling gait.

Difficulty initiating movement; once started, difficulty stopping.

Resting tremor that can be severe and distressing.

Motor symptoms emerge typically after 80% of substantia nigra dopaminergic neurons are lost.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Who is most affected by Parkinson’s disease and how common is it?

A

Primarily affects individuals over age 65.

Juvenile cases exist but are rare.

Second most common neurodegenerative disease after Alzheimer’s.

Affects 3–5% of people over 65.

Alzheimer’s affects 1 in 16 over 60 and 1 in 3 over 90.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What causes the clinical symptoms in Parkinson’s disease?

A

Loss of dopaminergic neurons in the substantia nigra.

Substantia nigra modulates motor signals via dopamine release.

Loss leads to impaired fine-tuning of voluntary movement.

Result: tremor, rigidity, bradykinesia, and postural instability.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What anatomical structure is primarily affected in Parkinson’s disease?

A

The substantia nigra in the midbrain.

It contains highly pigmented dopaminergic neurons.

In Parkinson’s disease, these neurons degenerate and lose pigmentation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why does Parkinson’s disease often go undiagnosed until late stages?

A

Neuronal death can occur over decades.

Remaining neurons compensate by taking over function.

Symptoms appear only after ~80% neuronal loss.

Leads to late diagnosis and limited treatment options.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How does the motor system control voluntary movement and how is it affected in Parkinson’s?

A

Movement is initiated in the motor cortex and modulated by midbrain regions like the basal ganglia and substantia nigra.

Dopamine modulates motor output: stimulates movement via basal ganglia.

Parkinson’s disrupts this modulation, causing unrefined or impaired movement (e.g., tremor, shuffling gait).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What experimental lesion model demonstrated the role of substantia nigra in motor control?

A

Lesion studies in rodents with electrodes targeting substantia nigra.

Sham: electrode inserted, no current — served as control.

Incomplete lesion: ~60% neuronal loss.

Complete lesion: ~70% loss, severe motor deficits.

Tyrosine hydroxylase staining confirmed neuronal loss.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What behavioural tests confirmed motor deficits in the substantia nigra lesion model?

A

Open field test: measured total distance travelled — less movement with more lesion.

Rotarod test: mice placed on rotating rod — those with lesions fell off faster due to motor weakness.

These tests showed direct link between substantia nigra loss and locomotor impairment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How did MPTP exposure reveal environmental causes of Parkinson’s disease?

A

In the 1970s–80s, young drug users in New York developed Parkinsonian symptoms.

They had accidentally synthesized MPTP, a neurotoxic contaminant.

MPTP caused selective death of dopaminergic neurons in the substantia nigra.

Led to early-onset, irreversible Parkinson’s symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What experiment confirmed MPTP causes dopaminergic neuron death?

A

Monkeys were injected with MPTP.

Substantia nigra showed massive neuron loss post-exposure.

Behavioural changes: decreased activity and motor dysfunction.

Dopamine injections temporarily restored movement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How did MPTP-treated monkeys behave compared to controls?

A

Control monkeys: Normal circadian movement — active periods and rest cycles.

MPTP monkeys: Severe reduction in movement.

Only active during dopamine administration.

Loss of substantia nigra neurons confirmed histologically.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How was rotenone used to investigate pesticide exposure and Parkinson’s?

A

Epidemiological links: farmers exposed to pesticides had higher Parkinson’s incidence.

Rotenone (a pesticide) was fed to transgenic fruit flies expressing green fluorescent dopaminergic neurons.

Dopaminergic neuron clusters degenerated after exposure.

Locomotor deficits confirmed by simple climbing assay (flies failed to ascend chambers).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What does rotenone exposure in flies show about Parkinson’s pathology?

A

Dopaminergic neuron degeneration is dose-dependent.

Locomotor impairment parallels human symptoms.

Suggests environmental toxins like rotenone can cause Parkinson’s via selective dopaminergic toxicity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are Lewy bodies and what proteins are they composed of?

A

Intracellular inclusions found in dying neurons in Parkinson’s disease.

Composed primarily of alpha-synuclein and ubiquitin.

Alpha-synuclein forms filamentous aggregates.

Ubiquitin tags indicate failed degradation attempts via the ubiquitin-proteasome system (UPS).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Why must researchers control for specificity in rotenone experiments?

A

Rotenone could non-specifically kill any neuron or cell type.

Control experiments must show selective dopaminergic neuron death.

Other neurons (e.g., cholinergic, GABAergic) must remain unaffected.

Ensures toxicity is relevant to Parkinson’s, not generalised cell death.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What does the presence of ubiquitin on Lewy bodies suggest?

A

Misfolded proteins are recognised and tagged for degradation.

However, degradation is not completed — proteins accumulate.

Implies dysfunction in the ubiquitin-proteasome system (UPS).

Supports the idea that defective protein clearance contributes to neuronal death.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the two main categories of causes for Parkinson’s disease?

A

Sporadic (unknown cause) — majority of cases.

Familial (genetic mutations) — minority of cases.

Some environmental factors are implicated in sporadic forms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Which environmental toxin was linked to Parkinson’s via drug users?

A

MPTP – neurotoxin accidentally synthesized in drug preparation.

Causes irreversible Parkinsonian symptoms.

Selectively targets substantia nigra neurons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Which genetic mutations are associated with juvenile-onset Parkinson’s disease?

A

Mutations in PINK1, Parkin, and DJ-1.

All are autosomal recessive.

Requires two copies of the mutated gene for disease expression.

Cause early (juvenile) or early-onset forms of Parkinson’s.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What do the autosomal recessive mutations in Parkin, PINK1, and DJ-1 imply about their function?

A

Suggest a loss-of-function mechanism.

One functional allele is sufficient for normal function.

Complete loss leads to disease.

Indicates their normal role is protective in neurons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

How is oxidative stress linked to Parkinson’s pathogenesis?

A

MPTP inhibits mitochondrial complex I → increased ROS.

DJ-1 protects against free radical damage.

PINK1 localises to mitochondria, suggesting a role in mitochondrial quality control.

Loss of these functions leads to accumulation of oxidative damage.

23
Q

What experiment supports oxidative stress as a pathogenic mechanism?

A

Animals exposed to MPTP or rotenone show increased oxidative stress markers.

Free radical probes confirm ROS presence in substantia nigra.

Antioxidant treatment (e.g., in DJ-1 mutant models) reduces damage.

Suggests ROS is causally linked to neuron death.

24
How does Parkin contribute to protein clearance and Parkinson’s pathology?
Parkin is an E3 ubiquitin ligase. Tags proteins like alpha-synuclein for degradation. Mutations lead to impaired tagging → protein accumulation. Supports a UPS failure model in Parkinson’s disease.
25
What does the aggregation of alpha-synuclein suggest about Parkinson’s pathology?
Mutant alpha-synuclein aggregates faster into filaments. Misfolded aggregates accumulate and resist clearance. Aggregates form Lewy bodies → disrupt cellular processes. Implicates protein misfolding and aggregation as central to disease.
26
What vicious cycle may develop involving the UPS and protein aggregation?
Aggregated proteins accumulate and overwhelm the UPS. This further reduces UPS capacity. Leads to more aggregation and stress. The cycle perpetuates degeneration of substantia nigra neurons.
27
What is the integrated pathogenic sequence proposed for Parkinson’s disease?
Environmental toxins or mutations cause oxidative stress. Oxidative stress → protein misfolding (e.g. alpha-synuclein). Misfolded proteins → tagged with ubiquitin. UPS dysfunction → failure to degrade → aggregation. Aggregates accumulate → Lewy body formation. Disrupts cellular functions and leads to neuronal death.
28
How can alpha-synuclein aggregation impair axonal transport?
Aggregates form space-occupying lesions. Block microtubule tracks for axonal transport. Disrupts delivery of materials between cell body and synapse. Adds to neuronal dysfunction beyond protein toxicity.
29
Why is the substantia nigra particularly vulnerable in Parkinson’s disease?
Unknown, but hypotheses include: Selective uptake of toxins (e.g. MPTP, rotenone). Reduced antioxidant capacity. Melanin pigment may play a role in vulnerability. Possible differences in clearance or metabolism.
30
What experimental model demonstrated MPTP’s effects on Parkinsonian symptoms?
MPTP-injected monkeys showed: Loss of substantia nigra neurons. Reduced locomotor activity. Dopamine injection temporarily restored movement. Confirmed causal link between MPTP toxicity and Parkinson’s-like pathology.
31
: How was rotenone used to test pesticide exposure as a Parkinson’s risk?
Fruit flies expressing GFP in dopamine neurons were fed rotenone. Result: reduced number of fluorescent dopaminergic neurons. Flies failed the climbing test → locomotor impairment. Proved rotenone selectively kills dopamine neurons.
32
What are the two key hypotheses tested with rotenone models?
Does rotenone selectively kill dopaminergic neurons? Does exposure lead to motor deficits similar to Parkinson’s? Positive results support causal link between pesticide exposure and disease.
33
What concerns were raised about using fruit flies for Parkinson’s modeling?
Rotenone might affect many cell types, not just dopaminergic. Flies may be inherently more sensitive to insecticides. Validity depends on showing rotenone selectively targets dopamine neurons.
34
What is the current hypothesis linking oxidative stress, UPS failure, and aggregation?
Oxidative stress → misfolded proteins. UPS dysfunction → failure to clear misfolded proteins. Aggregates accumulate → disrupt transport, damage cells. Leads to neuron death, especially in substantia nigra.
35
What is the prion-like hypothesis in Parkinson’s disease?
Suggests misfolded alpha-synuclein spreads neuron-to-neuron. Like prions, it seeds aggregation in connected neurons. Evidence: injected Parkinson’s brain lysate spreads through brain in animals.
36
What experimental evidence supports the prion-like hypothesis?
Alpha-synuclein-containing lysate injected into one brain region. Over time, aggregates appear in distant, connected regions. Implies trans-synaptic spread via anatomical circuits.
37
What are criticisms of the prion-like model in Parkinson’s?
In human Parkinson’s, pathology is mostly localized to substantia nigra. The animal model shows widespread spread, which may be irrelevant. Possibly reflects differences in alpha-synuclein behaviour between species.
38
What key principle should be considered when using animal models?
A good model must replicate the human condition. Otherwise, results may be irrelevant, even if scientifically accurate. Animal data should align with human pathology and symptoms.
39
What is the first-line therapy for Parkinson’s disease and why?
L-DOPA (Levodopa) is the primary treatment. It is a precursor to dopamine that crosses the blood-brain barrier. Temporarily restores movement by compensating for lost dopamine.
40
Why does L-DOPA therapy eventually become less effective?
It depends on remaining dopaminergic neurons to convert it. As more neurons die, conversion to dopamine declines. Eventually, too few neurons remain to sustain function
41
What other dopamine-based strategies are used in Parkinson’s?
MAO-B inhibitors: reduce dopamine breakdown. COMT inhibitors: prevent L-DOPA degradation. Dopamine agonists: directly stimulate receptors (e.g., apomorphine). Amantadine: promotes dopamine release.
42
What is deep brain stimulation (DBS) and how does it work?
Electrode implanted in brain (often near substantia nigra or STN). Delivers electrical pulses to mimic lost dopamine signalling. Immediate reduction in tremor and rigidity upon activation
43
What are limitations of deep brain stimulation (DBS)?
Highly invasive surgery with risk of infection or error. Requires specialist expertise and expensive equipment. Not suitable for many elderly patients due to surgical risks. Potential long-term side effects or immune responses.
44
What are disease-modifying therapeutic strategies in development?
Antioxidants: reduce oxidative stress. Anti-inflammatories: reduce neuroinflammation. Neurotrophic factors: promote neuron survival. Vaccines: target and clear alpha-synuclein aggregates.
45
What is the rationale behind using stem cell therapy in Parkinson’s disease?
Replace lost substantia nigra neurons using induced pluripotent stem cells (iPSCs). iPSCs can be derived from a patient's skin cells, reprogrammed, and differentiated. Goal: restore dopaminergic function and rescue movement.
46
What are challenges of stem cell therapy for Parkinson’s disease?
Surgical risk: deep brain implantation is complex. Immaturity: cells may not mature into true substantia nigra neurons. Tumor risk: stem cells may over-proliferate without control. Short-term benefit: new neurons may also degenerate over time. Ethical/legal constraints in many countries.
47
Why might stem cell therapy still be considered worthwhile despite its risks?
Even temporary restoration of function can improve quality of life. If degeneration takes decades, new cells may last long enough. Potential to customise therapy using patient's own cells.
48
Why is substantia nigra especially vulnerable in Parkinson’s disease?
Exact reason unknown, but hypotheses include: Increased oxidative stress susceptibility. Poor antioxidant defences. Melanin pigmentation may attract toxins. Toxin retention longer than in other neurons. Unique metabolic demands.
49
What is the proposed cascade of events in Parkinson’s pathogenesis?
Mitochondrial dysfunction (e.g., MPTP, rotenone exposure). Leads to oxidative stress and free radicals. Causes protein misfolding and aggregation (alpha-synuclein). Proteins are ubiquitinated but not degraded → accumulate. UPS failure and aggregate buildup (Lewy bodies). Disruption of axonal transport and synaptic function. Neuronal death in substantia nigra.
50
How can UPS failure contribute to Parkinson’s disease progression?
Misfolded proteins are tagged with ubiquitin for degradation. If proteasome function is compromised, tagged proteins accumulate. Aggregates block degradation pathways further → vicious cycle. Leads to cell stress, impaired function, and neuronal death.
51
What is the ‘shredder’ analogy used for the UPS in Parkinson’s disease?
UPS = cellular shredder for misfolded proteins. If it's clogged (e.g., due to excess alpha-synuclein), proteins accumulate. Overloaded UPS becomes completely ineffective, leading to cell death. Vicious cycle: accumulation → dysfunction → more accumulation.
52
What are consequences of alpha-synuclein aggregates within neurons?
Form Lewy bodies, occupy intracellular space. Interfere with organelle function and axonal transport. Impair communication between cell body and synapse. May also cause cellular toxicity and apoptosis.
53
Why might prion-like spread not occur in human Parkinson’s disease?
In humans, pathology remains localized to substantia nigra. Unlike Alzheimer’s, spread along circuits is not seen. Animal models may show spread, but don’t reflect human condition.
54
What qualities make a good animal model for human neurodegenerative disease?
Must replicate human pathology and progression. Should mimic the specific symptoms and affected regions. If the model shows effects not observed in humans, it may be irrelevant. Example: alpha-synuclein spreading in mice vs. localization in humans.